Search
Dazdotuftide
go.drugbank.com/drugs/DB21550InvestigationalDazdotuftide has a monoisotopic molecular weight of 1005.48 Da. … Dazdotuftide is a small molecule drug.
Muvalaplin
go.drugbank.com/drugs/DB21568InvestigationalMuvalaplin has a monoisotopic molecular weight of 710.4 Da. … Muvalaplin is a small molecule drug.
Pocenbrodib
go.drugbank.com/drugs/DB21616InvestigationalPocenbrodib has a monoisotopic molecular weight of 525.23 Da. … Pocenbrodib is a small molecule drug.
Perphenazine
go.drugbank.com/drugs/DB00850ApprovedInvestigationalAn antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine.
Mixtures: Etrafon D Tab, Etrafon A TabCategories: Dopamine D2 Receptor AntagonistsFerric maltol
go.drugbank.com/drugs/DB15598ApprovedInvestigational[A189291] Ferric maltol was initially granted FDA approval on July 25, 2019, for use in adults. … [A189288] Ferric maltol has been described in literature since at least the late 1980s as a potential treatment for iron deficiency.
Insulin aspart
go.drugbank.com/drugs/DB01306ApprovedInvestigationalMarketed as the brand name product NovoRapid, insulin aspart begins to exert its effects within 15 minutes of subcutaneous administration, while peak levels occur 30 to 90 minutes after administration. … If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening
Fluphenazine
go.drugbank.com/drugs/DB00623ApprovedA phenothiazine used in the treatment of psychoses. Its properties and uses are generally similar to those of chlorpromazine.
Categories: Dopamine D2 Receptor AntagonistsInternational brands: Dapotum DTrifluoperazine
go.drugbank.com/drugs/DB00831ApprovedA phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic.
Mixtures: CUAIT - D COMPRIMIDOS.Categories: Dopamine D2 Receptor AntagonistsLonafarnib
go.drugbank.com/drugs/DB06448ApprovedInvestigational[L23414, L23544] Lonafarnib was granted FDA approval on November 20, 2020, and is the first FDA-approved treatment for HGPS and other related progeroid laminopathies.[L23414, L23549] … aberrant farnesylated form of lamin A called progerin in the inner nuclear membrane.
Cysteamine
go.drugbank.com/drugs/DB00847ApprovedInvestigationalCystinosis is a rare disease caused by mutations in the CTNS gene that encodes for cystinosin, a protein responsible for transporting cystine out of the cell lysosome. … [L15606,L15616] In particular, cystine deposits on the eye can cause significant discomfort throughout the day and require frequent treatment with eye drops, typically every waking hour.